Literature DB >> 7093968

Cyclophosphamide-induced cardiomyopathy in the rat.

H A Hopkins, W L Betsill, A S Hobson, W B Looney.   

Abstract

Cyclophosphamide given to ACI inbred rats produced histologic evidence of cardiomyopathy and degenerative vascular changes beginning as early as 4 days after the first of three 150-mg/kg doses (0.9 g/m2). The interval between doses was 14 days to allow bone marrow to recover after each treatment. Twofold increases in heart weight and DNA content were observed 56 days after initial treatment; compensatory hypertrophy and a marked infiltration of the myocardium by lymphocytes were observed histologically at that time. Heart weight and DNA content were again at control levels on Day 126. Hydroxyproline content, which increased along with DNA and weight, did not decrease until after Day 196, confirming a morphologic finding of increased fibrosis after cyclophosphamide which eventually decreased in severity. These data re-emphasize the necessity for considering both the acute and chronic toxic effects, as well as recovery, when developing treatment schedules employing therapeutically effective chemotherapeutic agents.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7093968

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  5 in total

1.  Myocardial toxicity of high-dose cyclophosphamide in rabbits treated with daunorubicin.

Authors:  B Isberg; C Paul; L Jönsson; U Svahn
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 2.  Cyclophosphamide toxicity. Characterising and avoiding the problem.

Authors:  L H Fraiser; S Kanekal; J P Kehrer
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

3.  Transient, high-grade atrioventricular block from high-dose cyclophosphamide.

Authors:  Nayan Agarwal; Thomas A Burkart
Journal:  Tex Heart Inst J       Date:  2013

Review 4.  Myocardial diseases of animals.

Authors:  J F Van Vleet; V J Ferrans
Journal:  Am J Pathol       Date:  1986-07       Impact factor: 4.307

Review 5.  Doxorubicin (adriamycin) cardiomyopathy.

Authors:  E Saltiel; W McGuire
Journal:  West J Med       Date:  1983-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.